文献速递白血病

MEK1/2调控正常BCR与ABL1的抑癌功能从而决定TKI耐药Ph阳性白血病的ATO反应

MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.
PubMed 文献 · Leukemia · 2023-06-29

本研究揭示了一条MEK1/2/BCR::ABL1/BCR/ABL1信号环路:活化的MEK1/2与BCR::ABL1、BCR和ABL1形成五聚体复合物,诱导BCR及BCR::ABL1的Tyr360和Tyr177磷酸化以及ABL1的Thr735和Tyr412磷酸化,导致BCR抑癌功能丧失、BCR::ABL1致癌活性增强、ABL1胞质滞留和耐药。MEK1/2抑制剂可解离该复合物并恢复BCR抗肿瘤活性、促使ABL1核积聚,从而抑制白血病细胞生长并通过BCR-MYC和ABL1-p73轴使细胞对三氧化二砷(ATO)增敏;MEK1/2抑制剂Mirdametinib与ATO联用可延长BCR::ABL1-T315I诱导白血病小鼠的生存期。

要点

  • MEK1/2与BCR::ABL1、BCR和ABL1形成五聚体复合物,磷酸化BCR的Tyr360/Tyr177和ABL1的Thr735/Tyr412。
  • MEK1/2抑制剂解离复合物,恢复BCR抑癌功能并促使ABL1核积聚,抑制白血病细胞生长。
  • Mirdametinib与ATO联用显著延长BCR::ABL1-T315I诱导白血病小鼠的生存期。

核心结论

  • MEK1/2/BCR::ABL1/BCR/ABL1信号环路可能决定TKI耐药白血病患者对ATO的疗效。
  • MEK1/2抑制剂与ATO联合具有治疗TKI耐药白血病的治疗潜力。

研究设计与样本

  • 本研究为机制研究,包含细胞实验和BCR::ABL1-T315I诱导白血病小鼠模型实验。

主要发现

  • 活化的MEK1/2与BCR::ABL1、BCR和ABL1形成五聚体复合物,诱导BCR和BCR::ABL1的Tyr360和Tyr177磷酸化以及ABL1的Thr735和Tyr412磷酸化。
  • 上述磷酸化导致BCR抑癌功能丧失、BCR::ABL1致癌活性增强、ABL1胞质滞留和耐药。
  • MEK1/2抑制剂解离五聚体复合物,引起BCRY360/Y177、BCR::ABL1Y360/Y177和胞质ABL1Y412/T735去磷酸化,恢复BCR抗肿瘤活性并促使ABL1核积聚。
  • MEK1/2抑制剂通过激活BCR-MYC和ABL1-p73信号轴抑制白血病细胞生长并使细胞对ATO增敏。
  • 核ABL1的变构激活增强MEK1/2抑制剂Mirdametinib的抗白血病效应,Mirdametinib与ATO联用显著延长BCR::ABL1-T315I诱导白血病小鼠的生存期。

临床怎么用

  • 作者认为MEK1/2抑制剂与ATO联合具有治疗TKI耐药白血病的治疗潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Resistance to tyrosine kinase inhibitors (TKIs) remains a clinical challenge in Ph-positive variants of chronic myeloid leukemia. We provide mechanistic insights into a previously undisclosed MEK1/2/BCR::ABL1/BCR/ABL1-driven signaling loop that may determine the efficacy of arsenic trioxide (ATO) in TKI-resistant leukemic patients. We find that activated MEK1/2 assemble into a pentameric complex with BCR::ABL1, BCR and ABL1 to induce phosphorylation of BCR and BCR::ABL1 at Tyr360 and Tyr177, and ABL1, at Thr735 and Tyr412 residues thus provoking loss of BCR's tumor-suppression functions, enhanced oncogenic activity of BCR::ABL1, cytoplasmic retention of ABL1 and consequently drug resistance. Coherently, pharmacological blockade of MEK1/2 induces dissociation of the pentameric MEK1/2/BCR::ABL1/BCR/ABL1 complex and causes a concurrent BCRY360/Y177, BCR::ABL1Y360/Y177 and cytoplasmic ABL1Y412/T735 dephosphorylation thereby provoking the rescue of the BCR's anti-oncogenic activities, nuclear accumulation of ABL1 with tumor-suppressive functions and consequently, growth inhibition of the leukemic cells and an ATO sensitization via BCR-MYC and ABL1-p73 signaling axes activation. Additionally, the allosteric activation of nuclear ABL1 was consistently found to enhance the anti-leukemic effects of the MEK1/2 inhibitor Mirdametinib, which when combined with ATO, significantly prolonged the survival of mice bearing BCR::ABL1-T315I-induced leukemia. These findings highlight the therapeutic potential of MEK1/2-inhibitors/ATO combination for the treatment of TKI-resistant leukemia.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mazzera L, Abeltino M, Lombardi G, et al. MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia. Leukemia. 2023. PMID: 37386079. doi:10.1038/s41375-023-01940-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。